X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse PLETHICO PHARMA with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PLETHICO PHARMA   ACTAVIS
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ACTAVIS
Dec-14
PLETHICO PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs39517,481-   
Low Rs3110,663-   
Sales per share (Unadj.) Rs604.43,147.8-  
Earnings per share (Unadj.) Rs32.5-392.8-  
Cash flow per share (Unadj.) Rs51.3288.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs473.66,827.6-  
Shares outstanding (eoy) m34.08265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.5 7.9%   
Avg P/E ratio x6.6-35.8 -18.3%  
P/CF ratio (eoy) x4.248.7 8.5%  
Price / Book Value ratio x0.52.1 21.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,2623,741,736 0.2%   
No. of employees `000NA21.6 0.0%   
Total wages/salary Rs m1,5960-   
Avg. sales/employee Rs ThNM38,750.6-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM-4,835.7-  
INCOME DATA
Net Sales Rs m20,598837,013 2.5%  
Other income Rs m386-2,089 -18.5%   
Total revenues Rs m20,984834,924 2.5%   
Gross profit Rs m2,818107,526 2.6%  
Depreciation Rs m642181,244 0.4%   
Interest Rs m1,59326,401 6.0%   
Profit before tax Rs m969-102,208 -0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,497 0.0%   
Tax Rs m-138-5,255 2.6%   
Profit after tax Rs m1,107-104,450 -1.1%  
Gross profit margin %13.712.8 106.5%  
Effective tax rate %-14.35.1 -277.9%   
Net profit margin %5.4-12.5 -43.1%  
BALANCE SHEET DATA
Current assets Rs m18,877440,999 4.3%   
Current liabilities Rs m11,896321,618 3.7%   
Net working cap to sales %33.914.3 237.6%  
Current ratio x1.61.4 115.7%  
Inventory Days Days3658 61.9%  
Debtors Days Days19866 298.5%  
Net fixed assets Rs m9,861102,208 9.6%   
Share capital Rs m3410-   
"Free" reserves Rs m12,3310-   
Net worth Rs m16,1391,815,450 0.9%   
Long term debt Rs m4,706951,332 0.5%   
Total assets Rs m33,1463,327,123 1.0%  
Interest coverage x1.6-2.9 -56.0%   
Debt to equity ratio x0.30.5 55.6%  
Sales to assets ratio x0.60.3 247.0%   
Return on assets %8.1-2.3 -347.3%  
Return on equity %6.9-5.8 -119.2%  
Return on capital %12.3-3.0 -408.2%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Net fx Rs m1,2190-   
CASH FLOW
From Operations Rs m2,437143,731 1.7%  
From Investments Rs m-6,265-344,148 1.8%  
From Financial Activity Rs m2,490193,361 1.3%  
Net Cashflow Rs m-1,337-7,055 19.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.08 Rs / USD

Compare PLETHICO PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PLETHICO PHARMA With: WOCKHARDT LTD.  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE  ALKEM LABORATORIES  



Today's Market

Recovery of Global Markets, Apex Frozen Food IPO & Cues to Watch Out Today(Pre-Open)

Indian stock markets remained range-bound in lacklustre trade on Tuesday as market participants kept to the sidelines in the absence of clear triggers.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 8-QTR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS